KRMDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

KORU Medical Systems, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$3.02+0.02 (+0.67%)

Close on Oct 19, 2026

Market cap: $149.52M
P/E (TTM): –
Dividend yield: –

KORU Medical Systems, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2017 2017-02-28	FY 2016 2016-02-29	FY 2015 2015-02-28	FY 2014 2014-02-28	FY 2013 2013-02-28	FY 2012 2012-02-29	FY 2011 2011-02-28
Revenue	41	34	29	28	23	24	23	12	12	11	8.70	7.76	6.39	4.92
Cost of Revenue	16	12	12	13	9.72	9.24	8.31	4.72	4.64	4.56	3.39	2.82	2.25	1.66
Gross Profit	26	21	17	15	14	15	15	7.57	7.60	6.69	5.31	4.94	4.14	3.26
Research & Development	4.39	5.26	5.74	4.96	2.47	1.30	0.74	0.24	0.21	0.47	0.22	0.15	0.09	0.04
Selling, General & Admin	23	22	20	21	18	12	9.77	7.77	5.94	4.79	3.85	3.54	2.66	1.97
Operating Expenses	29	28	27	26	21	16	14	8.31	6.42	5.54	4.30	–	–	–
Total Costs & Expenses	–	–	–	–	–	–	–	–	–	–	7.69	6.70	5.10	3.73
Operating Income	-2.97	-6.45	-10	-11	-7.03	-1.25	0.59	-0.74	1.18	1.15	1.01	1.06	1.29	1.19
Interest Expense	–	–	–	–	–	–	–	0.00	0.00	0.00	0.00	0.03	0.03	0.04
Other Non-Operating Income	0.36	0.38	0.50	0.11	0.67	0.06	0.11	0.00	-0.01	0.01	0.00	-0.02	-0.01	0.00
Asset Impairment Charges	–	–	–	–	–	–	–	–	–	1.18	–	–	–	–
Gain (Loss) on Sale of Assets	–	-0.02	-0.06	–	0.00	0.02	0.05	–	-0.01	0.00	–	–	–	–
Legal Settlements	–	–	–	–	–	-2.45	-3.42	–	–	–	–	–	–	–
Pretax Income	-2.62	-6.06	-9.77	-11	-6.36	1.19	0.70	-0.78	1.14	1.07	1.01	1.04	1.28	1.19
Income Tax Expense	0.02	0.00	3.97	-2.01	-1.80	-0.02	0.13	-0.24	0.36	0.32	0.31	0.31	0.47	0.49
Net Income	-2.64	-6.07	-14	-8.66	-4.56	-1.21	0.56	-0.53	0.78	0.75	0.70	0.73	0.82	0.70
EPS (Basic)(per share)	-0.06	-0.13	-0.30	-0.19	-0.10	-0.03	0.01	-0.01	0.02	0.02	0.02	0.02	0.02	0.02
EPS (Diluted)(per share)	-0.06	-0.13	-0.30	-0.19	-0.10	-0.03	0.01	-0.01	0.02	0.02	0.02	0.02	0.02	0.02
Shares Outstanding (Basic, Weighted)(shares)	46	46	46	45	44	42	39	38	38	38	37	36	34	36
Shares Outstanding (Diluted, Weighted)(shares)	46	46	46	45	44	42	39	38	38	38	37	36	35	37
EBITDA	-2.16	-5.56	-9.40	-10	-6.57	-0.84	0.93	-0.44	1.45	1.43	1.24	1.25	1.39	1.26
Provision for Credit Losses	–	–	–	–	–	-0.01	0.00	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 62.4%
Operating margin: -3.7%
Net margin: -4.0%
Return on equity, FY2025: -15.6%

Financial strength

Current ratio: 2.72
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 115.4%

Valuation

P/E ratio: –
Price to sales: 3.31
Price to book: 8.28
Dividend yield: –